Paper Details

  1. Home
  2. Paper Details

Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells.

Author: AndoShotaro, ItoYoshinori, KawadaJun-Ichi, KimuraHiroshi, SatoYoshitaka, ToriiYuka, WatanabeTakahiro

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the effects of duvelisib, a dual inhibitor of PI3Kγ and PI3Kδ, on EBV-associated lymphoma cell lines. Duvelisib inhibited cellular growth and induced apoptosis in EBV-positive and -negative B cell lines, but not in T cell lines. The study also found that duvelisib suppressed the lytic cycle of EBV, suggesting that it may have therapeutic potential for the treatment of EBV-associated B cell lymphomas.
Paper Details　
Original Abstract of the Article :
Epstein-Barr virus (EBV) is a ubiquitous oncogenic virus that is associated with B cell lymphomas, including Burkitt lymphoma and Hodgkin lymphoma. Previous studies have shown that the phosphatidylinositol 3-kinase (PI3K)/Akt pathway is activated in EBV-associated lymphomas and can be a novel therap...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911584/

データ提供：米国国立医学図書館（NLM）

Duvelisib: A Potential Therapeutic for Epstein-Barr Virus-Associated Lymphomas

Epstein-Barr virus (EBV) plays a role in the development of certain B cell lymphomas. This study investigates the potential of duvelisib, a dual inhibitor of PI3Kγ and PI3Kδ, for treating EBV-associated lymphomas. The researchers examined the effects of duvelisib on the PI3K/Akt signaling pathway and its antitumor activity in EBV-positive lymphoma cell lines. Their findings suggest that duvelisib may hold promise as a therapeutic agent for EBV-associated lymphomas.

Duvelisib: A Promising New Approach to Treating EBV-Associated Lymphomas

The authors demonstrate that duvelisib exhibits antitumor activity against EBV-associated lymphoma cell lines, suggesting a potential new therapeutic approach for these malignancies. The study highlights duvelisib's ability to inhibit cellular growth, induce apoptosis, and suppress EBV lytic gene expression, indicating its potential to effectively target EBV-associated lymphomas. Further research is needed to validate these findings and explore duvelisib's clinical efficacy in treating these malignancies.

Implications for Cancer Treatment: New Hope for EBV-Associated Lymphomas

This research offers hope for patients battling EBV-associated lymphomas. The authors' findings suggest that duvelisib may hold promise as a therapeutic agent for these malignancies. This study encourages further investigation into the potential of duvelisib for treating EBV-associated lymphomas and other B cell malignancies. Just as a camel adapts to the harsh desert environment, researchers are constantly seeking new and effective treatments for cancer, and this study represents a promising step in that direction.

Dr. Camel's Conclusion

This study highlights the potential of duvelisib as a promising new therapeutic agent for EBV-associated lymphomas. Further research is needed to validate these findings and explore duvelisib's clinical efficacy in treating these malignancies. As a researcher, I am encouraged by the ongoing efforts to develop novel therapies for cancer, offering hope for patients battling these devastating diseases.

Date :
  1. Date Completed 2019-08-07
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

29522278

DOI: Digital Object Identifier

PMC5911584

Related Literature

Article Analysis
・Effects of duvelisib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.